Voyager Therapeutics registers Phase 1 dose-escalation trial of VY1706 in early Alzheimer's diseaseAug 13Trial updateVoyager TherapeuticsVY1706
Voyager reports Q2 2026 results, sets Q4 milestones for two Alzheimer's programsAug 6Quarterly updateVoyager TherapeuticsVY1706
Sign inSign in